Success Metrics

Clinical Success Rate

60.0%

Based on 3 completed trials

Completion Rate

60%(3/5)

Active Trials

1(17%)

Results Posted

100%(3 trials)

Terminated

2(33%)

Phase Distribution

Ph phase_1

33%

Ph not_applicable

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

2(33.3%)

N/ANon-phased studies

4(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Terminated(2)

Detailed Status

Completed3

Terminated2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

60.0%

Most Advanced

Phase 1

Trials by Phase

Phase 12 (33.3%)

N/A4 (66.7%)

Trials by Status

completed350%

recruiting117%

terminated233%

Recent Activity

1 active trials

Showing 5 of 6

recruitingphase_1

Clinical Trials (6)

Showing 6 of 6 trials

NCT06105931Phase 1

Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes

Recruiting

NCT04146909Not Applicable

The Effect of Lactation on Insulin Sensitivity and Lipolysis in Women

Terminated

NCT04759872Not Applicable

Insulin and Muscle Fat Metabolism

Terminated

NCT02717832Not Applicable

Protection Against Insulin Resistance in Obesity

Completed

NCT01474785Phase 1

RYGB and the Gastric Adipose Axis

Completed

NCT01833403Not Applicable

Metabolomic Analysis of Hepatic Insulin Resistance

Completed

All 6 trials loaded

Drug Details

Intervention Type: DIAGNOSTIC TEST
Total Trials: 6